

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number/Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1314	7,906,626 B2	03-15-2011	Raso	
	1275	2010/0266505 A1	10-21-2010	Black	
	1215	2009/0297511	12-03-2009	Schenk	
	964a	7,625,550	12-01-2009	Basi et al.	
	1192	7,582,733	09-01-2009	Basi et al.	
	1216	2009/0155256	6-18-2009	Black et al.	
	1290	2008/0031954 A1	02-07-2008	Paris et al.	
	1277	2007/0196375	08-23-2007	Tobinick	
	1210	2007/0072307 A1	03-29-2007	Godavari et al.	
	1196	7,147,851 B1	12-12-2006	Ponath et al.	
	1153 a	2006/0234912	10-19-2006	Wang et al.	
	1197	7,112,661 B1	09-26-2006	Miller	
	1278 a	2006/0193850	08-31-2006	Wame et al.	
	1195	6,824,780 B1	11-30-2004	Devaux et al.	
	708a	2003/0039845 A1	02-27-2003	Adair et al.	
	1211	6,432,710 B1	08-13-2002	Boss, Jr. et al.	
	1293 a	6,096,318	08-01-2000	Stevens et al.	
	1209	5,910,427	06-08-1999	Mikayama	
	1242	5,417,986	05-23-1995	Reid et al.	
	198a	5,004,897	04-02-1991	Pardridge	

U.S. PATENT APPLICATIONS

Examiner	Cite No. ¹	Document Number Number/Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1212	60/530,480	12-17-2003	Arumugham	

Examiner
SignatureDate
Considered¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

LFGA1.02/3280323.v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	1271	WO	10/044803	A1	04-22-2010			
	1102a	EP	1 690 547	B1	07-08-2009			
	1222	EP	1 185 298	B1	06-24-2009			
	1276	WO	09/052439	A2	04-23-2009			
	1135a	WO	08/131298	A3	10-30-2008			
	1223	WO	06/066171	A1	06-22-2006			
	1224	WO	06/066049	A2	06-22-2006			
	1206	WO	04/016282	A1	2-26-2004			
	54a	WO	99/60021	A2	11-25-1999			
	1267	WO	98/39303	A1	09-11-1998			
	1236	WO	98/08098	A2	02-26-1998			
	1274	WO	98/04720	A1	02-05-1998			
	1177	WO	97/40147	A1	10-30-1997			
	1178	WO	97/37031	A1	10/09/1997			
	1179	WO	97/36601	A1	10/09/1997			
	1180	WO	97/28816	A1	08-14-1997			
	1285	WO	97/013855	A1	04-17-1997			
	1238	WO	97/05164	A1	02-13-1997			
	1259a	WO	96/40895	A1	12-19-1996			
	1249	WO	96/33739	A1	10-31-1996			
	1181	WO	96/29421	A1	09-26-1996			
	1237	WO	96/22373	A1	07-25-1996			
	1182	WO	96/14081	A1	05-17-1996			
	1240	WO	96/03144	A1	02-08-1996			
	1220	WO	96/01126	A1	01-18-1996			
	1225	WO	95/05849	A1	03-02-1995			
	1228	WO	94/29459	A1	12-22-1994			
	1183	WO	94/21288	A1	09-29-1994			
	1184	WO	94/16731	A1	08-04-1994			
	1244	WO	94/17197	A1	08-04-1994			
	1185	WO	94/06823	A1	05-11-1994			

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 601.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
LEGAL62/32820323v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

1176	EP	616 814	A1	03-21-1994			
1175	EP	613007	A2	02-18-1994			
1227	WO	94/03208	A1	02-17-1994			
1258	WO	93/12227	A1	06-24-1993			
1251	WO	92/19267	A1	11-12-1992			
48a	EP	506 785	B1	10-07-1992			
1186	WO	92/16330	A1	09-17-1992			
1187	WO	92/07944	A1	05-14-1992			
1188	WO	92/05793	A1	04-16-1992			
1270	WO	92/01059	A1	01-23-1992			
1250	WO	91/19795	A1	12-26-1991			
1257	WO	91/10741	A1	07-25-1991			
1189	WO	90/14837	A1	12-13-1990			
1221	WO	90/07861	A1	07-26-1990			
1239	WO	90/05142	A1	05-17-1990			
1190	WO	87/06838	A1	11-19-1987			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901:04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

LEGAL02/32820323v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1317	"AAB-001 in Patients with Mild to Moderate Alzheimer's Disease" ClinicalTrials.gov last updated 9/22/2009 3 pages	
	1246	AGADJANYAN et al., "Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope From (beta)-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide," <i>J. Immunol.</i> 174:1580-1586 (2005).	
	1156	ALLEN et al., "Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer," <i>Arch. Neurol.</i> , 63(10): 1475-1478 (2006), abstract only.	
	1303	Aquila Press Release, PR Newswire. May 6, 1997	
	1218	AUCLAIR et al., "Effect of Active Immunization Against Oestradiol in Developing Ram Lambs on Plasma Gonadotrophin and Testosterone Concentrations, Time of Onset of Puberty and Testicular Blood Flow," <i>Journal of Reproduction and Fertility</i> , 104:7-16 (1995).	
	1283	AYLWARD et al., "Cerebellar Volume in Adults With Down Syndrome," <i>Arch Neurol.</i> , 4(2):209-212 (1997). Abstract only.	
	1299	BACH et al., "Vaccination with AB-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral AB and Lowers Plaque Burden in APP Transgenic Mice," <i>J. Immunol.</i> , 2009, 182 7613-7624	
	1253	BANDLOW et al., "Untersuchungen Zum Mechanismus Der Immunologischen Adjuvanswirkung des Vacciniavirus", <i>Archiv für die gesamte Virusforschung</i> , 38:192-204 (1972). German article.	
	1229	BARELLI et al., "Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases," <i>Molecular Medicine</i> , 3(10):695-707 (1997).	
	1263	BEGLEY, "Delivery of Therapeutic Agents to the Central Nervous System: The Problems and the Possibilities," <i>Pharmacol. Therapy</i> , 104(1): 29-45 (Oct. 2004).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
LEG/AL02/32S20323v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1849
Examiner Name	Gregory S. Ernich
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1191	BIEWENGA et al., "Cleavage of Protein A-binding IgA1 with IgA1 Protease From Streptococcus Sanguis." <u>Immunol Commun.</u> , 12(5):491-500 (1993), abstract only.	
	1219	BLACK et al., "A Single Ascending Dose Study of Bainezumab, A Humanized Monoclonal Antibody to A β , In AD." 9 th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, 1 page (April 20, 2006). Abstract only.	
	1298	BORASCHI et al., "Interleukin-1 and Interleukin-1 Fragments a Vaccine Adjuvants", <u>Methods</u> , 1999, 19, pgs 108-113	
	1207	BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," <u>Eur. J. Immunol.</u> , 17:1213-1215 (1987)	
	1306	BURBACH et al. "Vessel ultrastructure in APP23 transgenic mice after passive anti-A β immunotherapy and subsequent intracerebral hemorrhage" <u>Neurobiology of Aging</u> 28:202-212 (2007)	
	1204	BUTTINI et al., " β -Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease," <u>The Journal of Neuroscience</u> , 25(40):9096-9101 (2005).	
	1305	CHAUHAN et al. "Intracerebroventricular Passive Immunization With Anti-A β Antibody in Tg2576" <u>J of Neuroscience</u> 74:142-147 (2003)	
	1233	CHECK, "Nerve Inflammation Halts Trail for Alzheimer's Drugs," <u>Nature</u> , 415:462 (2002)	
	1322	CLAUDIO, "Ultrastructural features of the blood-brain barrier in biopsy tissue for Alzheimer's disease patients." <u>Acta Neuropathol.</u> 91:6-14 (1996)	
	1301	CONSTANTINO, Expert opinion 9/17/2010	
	1296	CRIBBS et al., "Adjuvant-dependant modulation of th1 and th2 responses to immunization with B-amyloid", <u>International Immunology</u> , 2003, vol. 15, No. 4, pgs 505-514	
	1318	Declaration of Dr. Matthias Staufenbiel Ph D. July 15, 2011	
	1292	DO et al., "Reprogramming Somatic Gene Activity by Fusion With Pluripotent Cells" <u>Stem Cell Reviews.</u> , 2:257-264 (2006)	
	1248	DONNELLY, "New Developments in Adjuvants," <u>Mechanism of Ageing and Development</u> , 93:171-177 (1997).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
LUGAL62/32820323v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1194	Ecuadorian Search Report of 07/02/2009 for Ecuador Patent Application No. SP 03-4685.	
	1309	Elian Reports First Quarter 2006 Financial Results. Business Wire (May 4, 2006) XP002620724	
	1310	Elian Reports First Quarter 2006 Financial Results. Business Wire (May 4, 2006) XP002620725	
	1304	European Search Report of 02/07/2011 for European Application EP 08 74 6362.6	
	1234	GAUTHIER et al., "Alzheimer's Disease: Current Knowledge, Management and Research," Can. Med. Assoc. J., "157:1047-1052 (October 15, 1997).	
	1269	Genbank Accession number AAD00856.1, "Igm Heavy Chain Variable Region [Homo Sapiens]." 07/31/2001.	
	1268	Genbank Accession number AAB35009.1, Wang et al., "Antidiotype Ig 1F7 Light Chain Variable Region [Human, 1F7 Hybridoma Cells, Peptide Partial, 120aa]." 10/28/1995.	
	1319	GHERSI-EGEA et al., "Fate of Cerebrospinal Fluid-Borne Amyloid β -Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries," <u>Journal of Neurochemistry</u> , Vol 67 No. 2:880-883 (1996)	
	1208	GHEITIE et al., "CD4 Peptide-Protein Conjugates, But Not Recombinant Human CD4, Bind to Recombinant gp120 From the Human Immunodeficiency Virus in the Presence of Serum From AIDS Patients," <u>Proc. Natl. Acad. Sci.</u> , 88:5660-5693 (1991).	
	1300	GHOCHIKYAN, "Rationale for Peptide and DNA Based Epitope Vaccine for Alzheimer's Disease Immunotherapy", <u>CNS Neurol Disord Drug Targets</u> , 2009; 8(2): 128 1-18	
	1205	GOLDING et al., "Vaccine Strategies: Targeting Helper T Cell Responses," <u>Annals New York Academy of Sciences</u> , 31:126-137 (1995).	
	1289	GREENBERG et al. "Amyloid Angiopathy-Related Vascular Cognitive Impairment" <u>Stoke</u> , 35:2616-2619 (2004)	
	1313	GREISMAN et al., "A General Strategy for Selecting High-Affinity Zinc finger Proteins for Diverse DNA Target Sites" <u>Science</u> Vol 275:657-661 (1997)	
	1315	GUSTAVSSON et al., "Mechanisms of Transferrin Amyloidogenesis Antigenic Mapping of Transferrin Purified from Plasma and Amyloid Fibrils and within in Situ Tissue Localizations" <u>American Journal of Pathology</u> 44(6):1301-1311 (1994)	

Examiner
SignatureDate
Considered¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional) ³ Applicant is to place a check mark here if English language Translation is attachedBurden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
LEGAL/02/32820323v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1255	HAMILTON, "Molecular Engineering: Applications to the Clinical Laboratory," Clin. Chem. 39(9):1988-1997 (1993).	
	1261	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 139-195 (1988).	
	1287	HARTWIG, "Immune ageing and Alzheimer's disease," <i>NeuroReport</i> , 6:1274-1276 (1995)	
	1230	HELLMAN et al., "Allergy Vaccines - A Review of Developments," Clin. Immunother., 6(2): 130-142 (Aug. 1996).	
	1260	HERMANSON et al., "Amino Acids as Spacers," <i>Immobilized Affinity Ligand Techniques</i> , section 3.1.1.5:150-152 (1992).	
	1200	HILLEN-MASKE et al., "Konichalcit", <i>Rompp Chemie Lexikon</i> , 9 th edition, pg. 2322 (1990).	
	1193	HOGARTH, Fc Receptors Are Major Mediators of Antibody Based Inflammation in Autoimmunity," <i>Current Opinion in Immunology</i> , 14:798-802 (2002).	
	1284	HOLM et al., "Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1," <i>Mol. Immunol.</i> , 44(6):1075-1084 (Feb 2007).	
	1236	HUANG et al., "Amyloid β -Peptide Possesses a Transforming Growth Factor- β Activity," <i>The Journal of Biological Chemistry</i> , 273(42):27640-27644 (October 16, 1998).	
	1262	HUDSON et al., "Antibody as a Probe," <i>Practical Immunology</i> , Chapter 2, pages 34-85 (1989).	
	1226	JANEWAY et al., <i>Immunobiology</i> , 3 rd edition, pages 2:7, 2:9, 2:12, 8:16-8:17, 12:43 (1997).	
	1243	JARRETT et al., "The Carboxy Terminus of the β Amyloid Protein is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease," <i>Biochemistry</i> , 32:4693-4697 (November 05, 1993).	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202

J.EGAL.02/32820323v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ?
	1252	JENNINGS, "Review of Selected Adjuvants Used in Antibody Production," <u>ILAR Journal</u> , 37(3) (1995).	
	1265	KALLBERG et al., "Prediction of Amyloid Fibril-Forming Proteins," <u>The Journal of Biological Chemistry</u> , 276(16):12945-12950 (April 20, 2001).	
	1231	KARDANA et al., "Serum HCG β -Core Fragment is Masked by Associated Macromolecules," <u>Journal of Clinical Endocrinology and Metabolism</u> , 71(5):1393-1395.	
	1254	KHAN et al., "Immunopotential and Delivery Systems for Antigens for Single-Step Immunization: Recent Trends and Progress," <u>Pharmaceutical Research</u> , 11(1):2-11 (1994).	
	1288	KIM et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of 1L-12 Expression Vector with a DNA Immunogen," <u>J. Immunol.</u> , 158:816-826 (1997).	
	1279	KINNECOM et al., "Course of Cerebral Amyloid Angiopathy? Related Inflation," <u>Neurology</u> , 68(17):1411-1416 (2007).	
	1280	KOFKE et al., "Remifentanyl-Induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE genotype," <u>Neurosurg Anesthes Neurol.</u> , 105(1):167-175 (2007).	
	1232	KOLLER et al., "Active Immunization of Mice with a A β -Hsp70 Vaccine," <u>Neurodegenerative Diseases</u> , 1:20-28 (2004).	
	1295	LEMERE, "Developing novel immunogens for a safe and effective Alzheimer's disease vaccine" <u>Prog Brain Res</u> , 2009; 175: 83 1-13	
	1264	MISRA et al., "Drug Delivery to the Central Nervous System: A review," <u>J. Pharm Pharm Sci.</u> , 6(2):252-273 (May 2003). Abstract.	
	1198	MITCHELL et al., "Prevention of Intracerebral Hemorrhage," <u>Current Drug Targets</u> , 8(7):832-838 (2007).	
	1311	MOUNT et al. "Alzheimer disease: progress or profit?" <u>Market Analysis Nature Medicine</u> 12(7) 780-784 (July 2006)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
1.FGAI.02/32R26323v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 11

Complete if Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Ernich
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1297	MOVSESYAN et al., "Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA epitope Vaccine - A Novel Immunotherapeutic Strategy", PLoS ONE, 2008, vol. 3, issue 5, e2124 1-13	
	1201	MUTSCHLER et al., "Arzneimittel-Wirkungen, Lehrbuch der Pharmakologie und Toxikologie," Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 6 th edition, pgs. 651-656 (1991), (German Article).	
	1247	NOVARTIS, "Novartis MF59 TM -Adjuvanted Influenza Vaccine (Fluad [®]) Significantly Reduces Hospitalization in Elderly," Novartis Press Release, October 19 2007.	
	1214	PCT International Preliminary Report on Patentability (Chapter I) of 10/20/2009 with Written Opinion of 10/03/2008 for application PCT/US2008/060926.	
	1217	PCT International Preliminary Report on Patentability (Chapter I) of 02/02/2010 for application PCT/US07/09499.	
	1316	PCT International Preliminary Report on Patentability (Chapter I) and Written Opinion Completed 12/22/2008 for PCT/US2008/060370	
	1282	PCT Search Report of 03/25/2009 for application PCT/US2008/80382.	
	1213	PCT Search Report of 10/09/2008 for application PCT/US2008/060926.	
	1281	PCT Written Opinion of 03/08/2009 for application PCT/US2008/80382.	
	1312	PLANT et al., "The Production of Amyloid β Peptide is a Critical Requirement for the Viability of Central Neurons," The Journal of Neuroscience, 23(13):5531-5535, (2003).	
	1321	PODUSLO et al., "Macromolecular permeability across the blood-nerve and blood-brain barriers." Proc. Natl. Acad. Sci USA . Vol 91 pp 5705-5709 (1994)	
	1266	RAMSHAW et al., "DNA vaccines for the treatment of autoimmune disease," Immunology and Cell Biology, 75:409-413 (1997)	
	1199	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," Nature, 332:323-327 (1988).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202 LFGAL02/3282032v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 11

Complete If Known

Application Number	10/544,093
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1272	SAIDO et al., "Amino-and-Carboxyl-Terminal Heterogeneity of β -Amyloid Peptides Deposited in Human Brain," <i>Neuroscience Letters</i> , 215:173-176 (August 8, 1996).	
	1202	SAIDO et al., "Autolytic Transition of μ -Calpain Upon Activation as Resolved by Antibodies Distinguishing Between the Pre- and Post-Autolysis Forms," <i>J. Biochem.</i> , 111:81-86 (1992).	
	1256	SHEEHAN et al., "The Utilization of Individual V _H Exons in the Primary Repertoire of Adult BALB/c Mice", <i>The Journal of Immunology</i> , 151(10):5364-5375 (November 15, 1993).	
	1203	SOOD et al., "Synthetic Peptides: A Modern Approach to Vaccination," <i>Indian Journal of Experimental Biology</i> , 34:849-861 (1998).	
	1273	<i>Stedman's Medical Dictionary</i> , 27 th Edition, "Vaccine," page 1922, lines 1-3 (2000).	
	1241	TAHTINEN et al., "Minimal Size of HIV-1 NEF ANTIGENIC EPITOPES RECONIZED BY HUMAN SERA," <i>Int. Conf. AIDS</i> June 16-21 1991, Published June 1991, abstract no. W.A. 1334.	
	1294	TAM, "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system", <i>Proc. Natl. Acad. Sci.</i> , 1998, vol. 85, pgs 5409-5413	
	1307	VASTAG, "Monoclonals expand into neural disorders" <i>Nature</i> 24:6 p 595-596 (June 2006)	
	1291	VISWANATHAN et al., "Cerebral Microhemorrhage", <i>Stroke</i> , 37:550-555 (2006)	
	1293	WANG et al., "Site-specific UBItH amyloid- β vaccine for immunotherapy of Alzheimer's disease" <i>Vaccine</i> 25 (2007) 3041-3052	
	1302	WEHNER, Declaration May 21, 2007	
	1245	WELLING et al., "Choice of Peptide and Peptide Length For the Generation of Antibodies Reactive With the Intact Protein," <i>FEBS Letters</i> , 182(1):81-84 (March 1985).	
	1308	WILCOCK, et al. "Deglycosylated anti-Amyloid- β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice" <i>Neurobiology of Disease</i> 26(20):5340-5346 (May 17, 2006)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attachedBurden Hour Statement: This form is estimated to take 2-3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
LEGAL/02/32820323v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 11

Complete if Known

Application Number	10/544,083
Filing Date	March 3, 2006
First Named Inventor	Ted Yednock
Art Unit	1649
Examiner Name	Gregory S. Emch
Attorney Docket Number	057436-392276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ‡
	1320	ZLOKOVIC et al., "Blood-Brain Barrier Transport of Circulating Alzheimer's Amyloid β." <u>Biochemical and Biophysical Research Communications</u> , Vol 197, No. 3, pp 1034-1040 (1993)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 202
LEGAL/02/32820323v1